Following the observation that smokers with NSCLC seem to derive improved benefit from anti-PD-1 agents [166], it was postulated that this effect may be a surrogate marker for an increased mutational load and subsequent increased neoantigen production and exposure and more effective immune response in patients chronically exposed to a strong mutagenic factor such as smoking. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.